Novel ar/ar-v7 and mnk1/2 degrader, vnpp433-3: molecular mechanisms of action and efficacy in ar-overexpressing castration resistant prostate cancer in vitro and in vivo models

HIGHLIGHTS

• who: Elizabeth Thomas and collaborators from the Department of Pharmacology, University of Maryland School of Medicine, West Baltimore Street, Baltimore, MD, USA have published the research: Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models, in the Journal: Cells 2022, 2699 of 31/01/2022
• what: The authors report the mechanism of VNPP433-3β, a potent degrader of AR. AR-V7 lacks the LBD, and the authors are investigating a possible alternative mechanism of degradation . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.